Xeris Biopharma Holdings (XERS)

• Market cap: $676M
• 1 day: 3.54%
• 5 days: 20.60%
• 1 month: 22.97%
• 3 months: 22.63%
• 6 months: 61.99%
• Year to date: 26.88%
• 1 year: 95.11%
• 5 years: 118.41%
• 10 years: -78.29%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Employees: 377

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

263% more call options, than puts

Call options by funds: $857K | Put options by funds: $236K

182% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 11

88% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 32

22% more capital invested

Capital invested by funds: $183M [Q3] → $223M (+$39.4M) [Q4]

13% more funds holding

Funds holding: 143 [Q3] → 161 (+18) [Q4]

0.97% more ownership

Funds ownership: 43.16% [Q3] → 44.13% (+0.97%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 9% downside
• Avg. target: $6 37% upside
• High target: $8 82% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

Piper Sandler David Amsellem 57% 1-year accuracy 20 / 35 met price target	9% downside $4	Neutral Reiterated	7 Mar 2025
HC Wainwright & Co. Oren Livnat 48% 1-year accuracy 22 / 46 met price target	82% upside $8	Buy Reiterated	7 Mar 2025
Jefferies Glen Santangelo 50% 1-year accuracy 5 / 10 met price target	37% upside $6	Buy Reiterated	29 Jan 2025